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Abstract Binding of hemagglutinin-neuraminidase pro-
teins (HN) to sialylated receptors initiates the infection
process of several paramyxoviruses, whereas later in the
viral life cycle, the neuramindase (NA) activity of newly
synthesized HN destroys all receptors. Prior to NA action,
expressed HN has to bind the receptor. To evaluate this
HN–receptor complex with respect to receptor inactivation,
three temperature-sensitive Sendai virus HN mutants car-
rying amino acid exchanges at positions 262, 264 and/or
461 were created that uncoupled NA activity from receptor
binding at 39C. Interestingly, at elevated temperature,
when there is no detectable neuramindase activity, all
infected cells are protected against homologous superin-
fection. Mutated HN protein on the cell surface is mainly
bound to sialylated cell-surface components but can be
released by treatment with NA. Thus, continuous binding
to HN already inactivates the receptors quantitatively.
Furthermore, mutant HN bound to receptors is prevented
from being incorporated into virus particles in the absence
of NA. It is shown here for the ﬁrst time that during
paramyxoviral infection, quantitative receptor inactivation
already occurs due to binding of receptors to expressed HN
protein without involvement of NA and is independent of
NA activity of viral progeny. NA subsequently functions in
the release of HN from the complex, coupled with desial-
ysation of receptors. These ﬁndings could have implica-
tions for further antiviral drug development.
Introduction
Hemagglutinin-neuraminidase glycoproteins (HN) in the
envelope of several paramyxoviruses initiate the infection
processbybindingtocellularreceptors.Laterinthevirallife
cycle, HN expressed on the cell surface is thought to cause
destruction of the receptor, thereby preventing re-infection
by viral progeny and also homologous superinfection [22].
Both HN functions are based on its afﬁnity for sialylated
receptors [6, 42]. Diverse sialic-acid-containing cell-surface
components have been characterized [9, 19, 37], and struc-
tural studies on HN from NDV, hPIV3 and SV5 suggest that
one structurally ﬂexible sialic-acid-recognition site of HN
switches between a binding and a catalytic function [4, 16,
43]. This concept of a bifunctional HN site is further sup-
ported by work showing that both functions could be
simultaneously reduced or even abolished through the
binding of monoclonal antibodies or neuraminidase (NA)
inhibitors [12, 28, 41]. Using hemadsorption assays, it has
been shown that mutated HN, generated in transduced cells,
shows both reduced NA and reduced receptor-binding
activity [3, 13]. Hence, it seems that HN mutations induce a
defect in both functions simultaneously and that generation
of an HN protein that possess functional receptor-binding
activity but lacks NA activity should not be possible.
Until now, a possible participation of the receptor-
binding function in the process of receptor destruction
could not be examined using live virus. In earlier studies
on cell lines persistently infected with Sendai virus (SeV)
[14, 40], we demonstrated protection against homologous
superinfection, although hemadsorption speciﬁc for HN on
the cell surface was reduced by 50% [25]. In parallel, a
strong decrease in NA activity was detectable through
the inability to release hemagglutinated erythrocytes at
37C from virus–erythrocyte complexes. Based on these
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infections could contain an HN with uncoupled receptor-
binding and receptor-destroying functions: HN bound to
receptors would not be released for binding another sub-
strate as long as NA is not active and—as a consequence—
incorporation of HN into viral progeny could be hindered.
If the same mechanism would also apply to wild-type (wt)
infections, such ﬁndings could be relevant for further
development of antiviral drugs, which are currently mainly
focused on neuraminidase inhibition. However, in wild-
type infections, both processes occur very quickly due to
the high efﬁciency of NA and therefore could not be
investigated separately so far.
We decided to test our hypothesis under natural condi-
tions by infecting cells with SeV mutants carrying selected
mutations in the HN gene suspected to be responsible for
NA deﬁciencies. A 30% reduced NA activity was reported
for SeV Enders strain mutant ts 271, which has amino acid
exchanges at positions 262, 264 and 461 [29, 30] compared
to Enders wt, but this mutant is no longer available.
Compared to Sendai strain Fushimi HN, the Enders HN
shows a reduction in NA activity of 35% [8, 39] due to the
aa exchange E461K; therefore, we decided to create
mutants based on the Fushimi backbone.
The HN mutants examined in the present work possess
the amino acid exchanges A262T?G264R?E461K,
A262T?E461K or A262T?G264R. Exchanges at posi-
tions 262 and 264 are equivalent to those of mutant ts 271,
and an exchange at position 461 corresponding to that in
the Enders strain should further decrease NA activity. To
demonstrate NA-independent receptor inactivation by these
mutants speciﬁcally, homologous superinfection assays
with a Sendai challenge virus carrying an eGFP reporter
gene were employed as a very sensitive approach.
The three SeV HN mutants presented here showed a
temperature-dependent decrease in NA activity to unde-
tectable levels when the proteins were expressed at ele-
vated temperature. Binding of mutated HN to sialylated
receptors of infected cells already prevented homologous
superinfection, independent of NA activity.
Materials and methods
Cells and virus infection
LLC-MK2 cells (Rhesus monkey kidney, ATCC no. CCL
7.1) were purchased from Flow Laboratories and were
maintained in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (FCS).
Cell monolayers were consistently infected with Sendai
virus at an m.o.i. of C4 to achieve HN synthesis in C98%
of the cells. Virus adsorption was generally performed at
33C for 1 h, after which cells were incubated in serum-
free DMEM (DMEM
-) at the indicated temperatures.
Virus stock and FLAT assay
Virus stocks were prepared by infecting cell monolayers
for 46 h at 33C. Virus particles were activated by cleav-
age of the F0 protein into F1 and F2 by treatment with
acetylated trypsin (4 lg/ml ﬁnal concentration) for 1 h.
Virus stocks were stored in the vapor phase of liquid N2.
Virus titers were determined by the ﬂuorescence-linked
antibody titer (FLAT) assay. Cell monolayers (2 9 10
5
cells) in 24-well plates were infected with ten-fold serially
diluted virus suspensions and incubated at 33C. Two days
later, the cells were ﬁxed with methanol. Intracellular viral
proteins were detected with monospeciﬁc anti-N antibodies
generated in our laboratory, followed by incubation with
anti-rabbit antibodies labeled with Alexa Fluor 568 ﬂuo-
rescence dye (Molecular Probes). Fluorescent positive cells
were counted.
Generation of recombinant Sendai virus (rSeV) HN
mutants and rSeV P-EGFP
The construction of the complete cDNA of SeV (Fushimi
strain) has been described previously [17, 18]. Mutations in
the SeV genome at positions 7,476, 7,482 and 8,073 were
generated by using synthetic oligonucleotide primers, the
ExSite PCR-based mutagenesis kit (Stratagene, La Jolla),
the fusion PCR technique and standard cloning techniques
[11]. The presence of the desired mutations in the three
different HN mutants was conﬁrmed by nucleotide
sequencing. Details of the stepwise generation of the
mutated genomic cDNA can be obtained from the authors
on request.
Generation of rSeV P-eGFP, which has the enhanced
green ﬂuorescent protein (eGFP) gene inserted after the P
gene, has been described previously [2]. Rescue of the
recombinantSeVHNmutantswasperformedwithMVA-T7
vaccinia virus as described previously [18, 33, 36].
Generation of recombinant measles virus P-DsRed
The construction and generation of the recombinant
measles virus P-DsRed (Schwarz strain, Me ´rieux
TM) with a
Discosoma red (DsRed) gene inserted after the P gene was
performed essentially as described previously [21].
Western blot analysis of cellular and viral proteins
Cell infection was performed in T75 Roux bottles (6 9 10
6
cells) as described above. After incubation for 47 h, the
culture medium was collected for virus puriﬁcation.
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debris by centrifugation at 700g, and virus particles were
pelleted at 30,000 rpm. (154,000g). The virus pellet was
solubilized in RIPA buffer, and the protein concentration
was determined. Infected cell monolayers were washed and
collected in DMEM
-. The cells were lysed in RIPA buffer
[32], and DNA was disrupted by soniﬁcation (LKB
Instruments). The protein concentration of each sample
was determined by the Lowry technique [26].
Cellular and viral proteins were analyzed by western
blot after separation on a 10% sodium dodecyl sulfate
polyacrylamide gel. The proteins were transferred to an
Immobilon-PVDF membrane (Millipore) by electroblotting
in Tris–glycine buffer (20 mM Tris–HCl, pH 8.8, 150 mM
glycine) at 400 mA for 6.5 h. The membranes were
blocked with Roti-Block (Carl Roth GmbH), a polymer-
based blocking reagent, and then incubated for 1 h in HN-
or N-protein-speciﬁc antibodies, which were generated in
our laboratory. The blot was rinsed with TBST (10 mM
Tris–HCl, pH 8.8, 150 mM NaCl, 0.05% Tween 20) and
incubated with peroxidase-conjugated anti-mouse or anti-
rabbit antibody (Dako) diluted in TBST. ECL western
blotting reagents (Amersham Biosciences) were used for
chemiluminescence detection.
Cell-surface immunoﬂuorescence
Cells grown on glass slides were infected for 24 h at 33 or
39C. The cells were incubated with anti-HN monoclonal
antibody S2, courteously provided by Portner et al. [31]. It
was added to the living cells for 1 h at room temperature.
After washing the cell monolayers, the cells were ﬁxed for
10 min with 100% methanol. HN protein-antibody com-
plexes were made visible by incubation in anti-mouse
Alexa Fluor 568-conjugated antibody (Molecular Probes)
for 1 h. Cells were photographed at 2009 magniﬁcation.
Erythrocyte binding assay and treatment of infected
cells with Vibrio cholerae neuraminidase (V.C. NA)
Erythrocytes of type O were freshly obtained from human
blood. Cells were seeded in 24-well plates with 1.6 9 10
5
cells/well and incubated for 1 day at 37C. Subsequently,
the cell monolayers were infected for 24 h as described
above. Hemadsorption activity (HAd) was determined
using a 0.5% erythrocyte suspension in serum-free med-
ium. After washing the cells, erythrocytes were added in
DMEM
- for 1 h at 4C. Unbound erythrocytes were
removed by washing, and the percentage of hemadsorp-
tion-positive cells was determined. Alternatively, the
hemoglobin content of bound erythrocytes was determined:
Erythrocytes were eluted by treatment for 2 h at 37C with
1 mU of V.C. NA (Sigma), pelleted and lysed in 50 mM
NH4Cl. The lysate was clariﬁed by centrifugation, and the
absorbance of the hemoglobin was measured at 450 nm
using a microtiter plate reader (Dynatech MR7000).
V.C. NA treatment was performed 23 h after cell
infection at the temperature used for production of HN
proteins. The monolayer was washed with DMEM
-, and
10 mU of V.C. NA was added in 250 ll DMEM
- for 1 h.
HAd activity was determined after removing the enzyme.
Detection of neuraminidase activity by substrate
cleavage
Assays were performed in T12.5 Roux bottles (1 9 10
6
cells). Monolayers were infected as described above. Cells
were washed and subsequently incubated in 0.4 ml color-
less Medium 199 (Gibco-Invitrogen) without FCS. NAe
substrate X-Neu5Ac (5-bromo-4-chloro-3-indolyl a-D-N-
acetylneuraminic acid, 0.2 lmol) (Sigma) [7] was added
for 1 h at the indicated infection temperatures. Afterward,
the supernatant was centrifuged through an Ultrafree-MC
centrifugal ﬁlter unit (Millipore) for 2 min at 8,000g
(Beckman centrifuge), and the ﬂow-through was trans-
ferred to a polystyrol cuvette. NA activity converted
X-Neu5Ac to the blue pigment 5,50-dibromo-4,40-dichloro
indigo, which was quantiﬁed 24 h later at 660 nm in a
spectrophotometer (Beckman).
Superinfection assays
Assays were performed in T25 Roux bottles (2 9 10
6
cells). Primary infection was carried out as described
above. The infected cells were washed 24 h later with
DMEM
-. Homologous superinfection was initiated by
adding rSeV P-eGFP [2] at an m.o.i. of C4. Measles virus
P-DsRed at an m.o.i. of C2 was used for heterologous
superinfection. The challenge virus was allowed to adsorb
for 1 h at the temperatures used for primary infection. Cells
were inspected for eGFP or DsRed after 2 and 3 days,
respectively.
Results
Production of SeV HN mutants and characterization
of the expressed HN proteins
HN mutants HN-262?264?461 (A262T?G264R?E461K),
HN-262?461 (A262T?E461K) and HN-262?264 (A262T?
G264R), based on wild-type (wt) SeV Fushimi strain, were
generated using our well-established virus rescue system
[18]. Efﬁcient ampliﬁcation of stock viruses at 33C already
conﬁrmed the functional receptor binding of the mutants.
Mutant virus titers of about 10
8 infectious particles/ml
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8/ml, HN 262?461 2.1 9
10
8/ml, HN 262?264 2.9 9 10
8/ml) were comparable to
those of wt virus (5.1 9 10
8/ml), as determined by FLAT
assay. This method was used for quantifying infectious HN
mutants with presumably reduced efﬁciency for plaque
formation or binding of erythrocytes. Western blot analysis
of viral HN showed distinct signals without signiﬁcant dif-
ferences in quantity and quality between mutated and wild-
type proteins (Fig. 1a).
In the next step, the stable and efﬁcient expression of
mutant HN proteins in infected cells at 33 and 39C was
analyzed. Infections were generally performed using an
m.o.i. of C4, virus particles were adsorbed at 33C, and
cells were incubated at 33 or 39C. HN in cell extracts
prepared 46 h later were analyzed by immunoblot detec-
tion. Using a small amount of cell extract (5 lg) resulted in
clear HN signals with all three mutants at both tempera-
tures without detection of degradation products (Fig. 1a).
In contrast to our efﬁcient HN synthesis, in transduced
cells, in which the HN expression was restricted, either due
to a small number of transfected cells and/or a generally
low level of expression, 250 lg of cell extract or
immunoprecipitation of radioactively labeled proteins was
required for detection [10, 13]. Next, mutant HN expressed
on the cell surface was detected in situ by cell-surface
immunoﬂuorescence. Incubation with the primary antibody
was carried out before cell ﬁxation. In this way, the
undesired permeabilization of cell membranes, which
could lead to binding of intracellular HN protein to the
antibody, was deﬁnitely prevented [5]. Transport to the cell
surface was independent of incubation temperature, since
mutated HN were clearly detectable at 33 and 39C
(Fig. 1c). HN signals on the cell surface were more regu-
larly distributed compared to the signals of cytoplasmic
proteins. Unimpaired expression of mutant HN and trans-
port to the cell surface were important prerequisites for
investigating HN–receptor complexes.
Finally, the neuraminidase (NA) activity of mutant HN
suspected to be decreased at elevated temperature was
measured at 33 and 39. In comparison to wt infected cells,
mutant cells infected at 33C revealed signiﬁcantly reduced
but clearly detectable neuraminidase. At 39C, activity was
undetectable (Fig. 1b). In this assay, even low levels of
sialidase activity should be detectable due to repeated
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Fig. 1 Characterization of mutant HN proteins. LLC-MK2 cells were
infected with wt SeV or HN mutants at an m.o.i. of C4. a For
detection of HN protein in virus particles, cells were cultured at 33C
for 47 h. Virus particles were concentrated by ultracentrifugation of
cell supernatants. Virus pellets were solubilized in RIPA buffer, and
the protein concentration was determined. Virus proteins (1 lg per
lane) were separated by SDS–PAGE. Immunodetection was per-
formed with an HN-speciﬁc (VII3c-4F) monoclonal antibody. For
detection of cytoplasmically expressed viral proteins, cells were
cultured at 33 or 39C for 46 h. Cell extracts were prepared, and
proteins (5 lg per lane) were separated by SDS–PAGE. Immunode-
tection was performed with an HN-speciﬁc (VII3c-4F) monoclonal
antibody. b Neuraminidase assays were carried out 24 h after
infection with X-Neu5Ac as substrate [7]. c For detection of mutant
HN on the cell surface by immunoﬂuorescence, binding of anti-HN
S2 antibodies [30] was performed 24 h after infection, followed by
ﬁxation with methanol. Anti-mouse Alexa Fluor 568-conjugated
antibody was used as a secondary antibody
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123binding and cleavage of the synthetic substrate. However,
when the substrate incubation time was extended to 4.75 h,
we again failed to detect any enzymatic activity (data not
shown). In summary, cytoplasmic mutant HN synthesis and
its transport to the cell surface are not impaired and NA
activity is undetectable at 39C, as proposed. Therefore,
these virus mutants should be useful tools for investigating
possible inﬂuences of HN–receptor complexes on receptor
inactivation.
Homologous superinfection by challenge virus carrying
a reporter gene
Superinfection assays should be employed for very sensi-
tive detection of functional receptors on the cell surface.
Homologous superinfection can be detected easily by using
recombinant SeV P-eGFP as challenge virus, which con-
tains the gene for the enhanced green ﬂuorescent protein
(eGFP) [2]. To optimize this system, LLC-MK2 cells
infected with wt SeV were analyzed for protection against
superinfection 5 and 24 h p.i. to mimic the unprotected and
the protected state, respectively. We assumed that pro-
gression to the protected state depends on the synthesis of
increasing amounts of HN during the course of infection.
As shown in Fig. 2a, distinct eGFP signals indicated
homologous superinfection of cells infected with wt SeV
for 5 h and with challenge virus for 2 days. Due to the
mixed infection with SeV P-eGFP and wt SeV, eGFP
signals were less intense than in cells infected only with
SeV P-eGFP (Fig. 3a, SeV-eGFP infection). However,
when the challenge was performed 24 h after primary
infection, homologous superinfection was no longer
detected (Fig. 2b). As a control, primary infection by SeV
wt was detectable in all cells by FLAT assay (Fig. 2c). The
newly developed method of homologous superinfection by
challenge virus carrying a reporter gene conﬁrmed that
SeV wt infection enables cells to build up quantitative
protection against further homologous virus infections
within 24 h. Moreover, this technique proved to be a sen-
sitive system for in situ detection of non-inactivated SeV
receptors on the surface of individual cells.
HN 26212641461 and HN 2621461 protein
expression induces protection against homologous
superinfection
Homologous superinfection assays were employed to test
infected but NA-negative cells for presentation and
accessibility of functional SeV receptors on the cell sur-
face. LLC-MK2 cells were infected with HN mutants. After
24 h, one set of infected cultures was subjected to
hemadsorption tests, the other treated with challenge virus.
After incubation with challenge virus for 47 h, there was a
lack of eGFP signal, indicating that the cells infected with
HN 262?264?461 and HN 262?461 had been able to
develop complete protection against homologous superin-
fection (Fig. 3a). Interestingly, resistance to SeV superin-
fection could be also demonstrated in cells lacking HAd
activity. The rare detection of single cells with very intense
ﬂuorescence signals (Fig. 3a, 262?264?461, 33C) was
attributed to cells that remained uninfected by mutant
viruses. These strong eGFP-speciﬁc signals are comparable
to those in cells infected with SeV P-eGFP alone (Fig. 3a,
SeV-eGFP infection).
In contrast, only partial protection against superinfection
was achieved in cells infected with mutant HN 262?264
(Fig. 3a). Homologous superinfection was identiﬁed in
only a few cells at 33C but by most of the cells at 39C:
HN 262?264 was not able to induce a complete and
temperature-independent inactivation of receptors. Super-
infection was also detectable at an increased m.o.i. of up to
75 as well as after prolonged infection times of up to 48 h
before challenge (data not shown). Quantitative protection
against homologous superinfection was ﬁnally reached
when cells infected at 39C with mutant HN 262?264
were subsequently treated with V.C. NA (Fig. 3a,
262?264?NA). Therefore, superinfection at 39C can be
interpreted as a temperature-sensitive effect on HN
262?264 binding activity.
To exclude any non-speciﬁc effects on HN–receptor
inactivation due to infection with mutants HN
262?264?461 and HN 262?461, heterologous superin-
fection assays with recombinant measles virus containing
Fig. 2 Optimization of superinfection with homologous SeV. Cells
were infected with wt SeV at 33C (m.o.i.[4) and challenged after
5ha or 24 h b with SeV P-eGFP (m.o.i.[4), and eGFP-speciﬁc
ﬂuorescence was detected after 48 h. c Cells infected with wt SeV at
33C (m.o.i.[4) were tested for infection by the FLAT method
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shown with HN 262?461 infected cells, measles challenge
virus infection and replication were not impeded (Fig. 3b).
Taken together, infection with NA-deﬁcient mutants pro-
tects cells against homologous superinfection. Thus, earlier
ﬁndings obtained with persistently infected cells [25] could
Fig. 3 Protection of SeV HN-mutant-infected cells against superin-
fection. a LLC-MK2 cells were infected with one of the three HN
mutants (m.o.i. C 6) and subjected to a hemadsorption test 24 h p.i.
(HAd). Parallel cultures were challenged 24 h p.i. with SeV P-eGFP
(m.o.i. C 4) and examined for eGFP ﬂuorescence 47 h after challenge
(SeV-eGFP superinfection). HN 262?264-infected cells (39C) were
treated additionally for 30 min with NA prior to challenge
(262?264?NA); LLC-MK2 cells infected only with SeV P-eGFP
(SeV-eGFP infection); b LLC-MK2 cells were infected with mutant
262?461 and challenged 24 h later with MeV P-DsRed (m.o.i. C 2)
Ds-Red ﬂuorescence was determined 70 h after challenge (MeV-
DsRed superinfection). Distinct cytopathic effect (CPE) of cells by
heterologous superinfection is shown. Cells were infected with MeV
P-DsRed only (MeV-DsRed infection)
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123be reproducedby using recombinant virus carryingonlytwo
or three deﬁned mutations within the HN gene.
HN–receptor complexes on the surface
of mutant infected cells
Another ﬁnding from earlier experimentation with
persistently infected cells was a signiﬁcantly reduced
hemadsorption (HAd) activity at elevated temperature.
Theoretically, mutated HN protein whose receptor-binding
site is occupied by sialic acid should not be able to bind
additional ligands. Therefore, mutated HN on the cell
surface were tested for HAd activity. When infected with
wt virus, all cells were capable of binding erythrocytes at
both temperatures, 33 and 39C (Fig. 4b). A comparable
situation was found when cells were infected with HN
mutants at 33C, showing B85% HAd activity (Figs. 3a,
4b). However, when infection with the mutants was carried
out at 39C, the HAd activity decreased drastically to only
15% (Figs. 3a, 4a, b).
To test whether the receptor-binding site of HN was
blocked by sialylated cell-surface components, the cells
were treated with exogenous NA and subsequently tested
for HAd activity. Like SeV neuraminidase, V.C. NA pref-
erentially hydrolyzes a (2, 3) linkages of sialic acids [24].
After V.C. NA treatment, erythrocyte binding was greatly
enhanced at 39C on cells infected with either HN mutant
262?264?461 or 262?461, whereas cells infected with
HN mutant 262?264 showed a minor effect (Fig. 4a, c).
The remaining HAd-negative cells during 262?264 infec-
tions might have been due to inefﬁcient extracellular
neuraminidase treatment, which is also unable to com-
pletely prevent LLC-MK2 cells from being infected with
SeV wt (data not shown).
These results now allow an explanation of superinfection
protection after infection with NA-deﬁcient HN mutants:
Mutant HN protein expressed in increasing amounts binds
to receptors, leading to a quantitative formation of the HN–
receptor complex and—when this binding persists—to a
quantitative inactivation of the receptor.
Reduced incorporation of HN into mutant virus
particles at 39C
HN incorporation into new virus particles could be hin-
dered when shortly after de novo synthesis of HN protein
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Fig. 4 Characterization of
receptor binding to mutant HN.
a Cells infected with HN
262?264?461, HN 262?461
or HN 262?264 and incubated
at 39C for 24 h were treated
with V.C. NA or not treated and
tested for erythrocyte binding at
4C (HAd). b, c Cells infected
with wt SeV or HN mutants at
an m.o.i. of B40, leading to
100% HAd activity at 33C.
b After incubation for 24 h at 33
and 39C, a 0.5% suspension of
human erythrocytes was added
for 1 h at 4C. Unbound
erythrocytes were removed, and
the percentage of cells covered
with erythrocytes was
determined. c Infected cells
were treated prior to the HAd
test with 10 mU V.C. NA for
1 h, and HAd activity was
determined after removing the
enzyme by extensive cell
washing
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123all of the HN is bound to receptors and these complexes
persist. Earlier results revealed that growth of a genetically
modiﬁed HN-negative mutant was unimpaired by the
presence of HN protein and that the HN content of virus
particles was drastically reduced when infections with the
NA-deﬁcient Sendai virus mutant ts 271 were performed at
39C[ 17, 29, 35]. It therefore seemed probable that
without interference with release of viral progeny, budding
particles could contain less HN. Therefore, HN mutant
particles propagated at 39C were tested for HN insertion.
To allow expression of the NA-inhibited HN phenotypes,
cells were infected with stock virus generated at 33C and
incubated for 48 h at 39C—long enough to a generate
sufﬁcient amount of progeny virus. Analysis of released
viral particles revealed a signiﬁcantly reduced HN content
for all three mutants (Fig. 5). The most drastic effect was
observed with HN mutant 262?461, which appeared to be
released without any HN proteins. Only by overexposing
the western blot was a faint signal obtained (data not
shown). A similarly diminished HN content was detected
with HN 262?264?461, showing only 10% of the HN
quantity detected in wt particles, whereas in mutant HN-
262?264, a relatively moderate but also clearly reduced
HN content (25%) was observed (Fig. 5). These results
indicate that HN insertion into SeV depends on functional
NA. In cells infected with NA-deﬁcient HN mutants
262?461 and 262?264?461, HN proteins were
continuously engaged in receptor binding, and therefore
incorporation into viral progeny was hindered.
Discussion
In the present work, the question is addressed whether SeV
HN with functional binding activity but defective NA is
capable of receptor inactivation. It is well known that the
ﬁrst step in the receptor-destruction process is a temporary
binding of HN to receptors, rapidly followed by cleavage
of sialic acid by NA. These consecutive processes happen
very quickly and could not be separated so far. Based on
data on Sendai virus mutants from persistent infections
[25], we suspected that for quantitative receptor inactiva-
tion, continuous binding to newly synthesized HN might be
sufﬁcient without any NA activity. To answer the question
of whether NA-deﬁcient HN mutants are able to inactivate
receptors quantitatively, for the ﬁrst time, superinfection
assays were employed as a highly sensitive test system
using eGFP-expressing Sendai virus as homologous
challenge virus. These assays allow detection of single
challenge virus entry via non-inactivated virus receptors on
infected cells, which was not possible in earlier transduc-
tion or superinfection studies based on viral progeny
[10, 15, 22].
Superinfection protection requires efﬁcient binding of
mutant virus to cells and efﬁcient HN production in
infected cells. The receptor-binding activity of mutated HN
was demonstrated by determining infection rates of the
mutant viruses, which were comparable to the wt virus.
Normal quantities of mutant HN in the cytoplasm and on
the surface of infected cells were detectable (Fig. 1a, c). In
contrast to our approach, this state was not attained in cells
transduced with wt hPIV3 HN or the NA-deﬁcient mutant
HN (C28a), since homologous superinfection was detect-
able [10]. In order to achieve efﬁcient superinfection pro-
tection, the time point of challenge virus addition has to be
chosen carefully. After an infection time of 5 h, ca. 50% of
the cells were unprotected against superinfection, whereas
24 h after primary infection, cells could no longer be
infected by the challenge virus (Fig. 2a, b). We suppose
that during progress of virus replication, the number of
newly synthesized HN proteins exceeds that of the receptor
molecules.
Newly synthesized HN 262?264?461 and 262?461
quantitatively blocked homologous superinfection of cells,
and this was independent of the infection temperature
(Fig. 3a), whereas the challenge virus alone efﬁciently
expressed ﬂuorescence in unprotected cells. The results of
homologous (Fig. 3a) and heterologous superinfection
(Fig. 3b) assays reveal that mutant HN blocks homologous
superinfection speciﬁcally and not only due to cellular
262
264
461
- HN
- N
0.25     0.5        1                      2 µg
wt 262
461
262
264
Fig. 5 HN protein content in mutant virus progeny generated at
39C. Virus production was performed essentially as described in
Fig. 1a. Protein separation by SDS–PAGE was performed with
quantities corresponding to 1/60 of the respective total virus protein.
Immunodetection was performed with HN-speciﬁc (VII3c-4F) mAB
and monospeciﬁc anti-N serum. Signals of diluted and undiluted N
protein served as an internal control and for quantiﬁcation. X-ray
ﬁlms were exposed to antibody-treated membranes for about 4 s
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123stress caused by the infection process. Hemadsorption on
the cell surface can be restored by NA treatment and HN
incorporation into viral progeny is restricted by continuous
binding to sialylated receptors. Therefore, it is more likely
that receptors are present but inactivated through binding to
HN than that viral infection downregulates receptor syn-
thesis, as believed in the case of the lentivirus CD4
receptor [27]. These experiments clearly demonstrate that
in the absence of NA activity, receptors remain bound to
HN, leading to protection against superinfection, and that
binding of mutant HN to receptors is reversible—by
application of external neuraminidase.
Cells infected with HN mutant 262?264 at 33C
blocked superinfection almost completely, whereas at
39C, infected cells were clearly superinfected (Fig. 3a).
This result suggests that a HN phenotype with insufﬁcient
receptor-binding afﬁnity was obtained at elevated temper-
ature. The HN-binding activity by mutant 262?264 does
not seem to be strong enough to inactivate receptors
completely, thus allowing homologous superinfection.
A number of mutated HNs generated by different lab-
oratories [3, 13, 34] were characterized in hemadsorption
and NA assays as HN variants with simultaneously
reduced binding and NA activity. These results are based
on the assumption that the ligands had unrestricted
accessibility to HN. However, when HN cannot be
released from the receptor due to the lack of NA, HN, in
turn, would not be available to bind other ligands, such as
erythrocytes. Thus, interpretations of results from previous
hemadsorption and NA assays typically employed in this
type of study should be reconsidered [3, 34]. According to
our results, newly synthesized HN is ﬁrst targeted to
binding to receptors. Consequently, only after NA is active
and removed bound receptors can HN attain the ability to
bind erythrocytes. The conclusion that HAd binding
activity depends on the efﬁciency of NA in releasing HN
from HN–receptor complexes was conﬁrmed in various
ways: (1) Most of the cells infected with the HN-
262?264?461 or HN-262?461 mutant lost the HAd
activity they had at 33C when the infection temperature
was increased, concomitantly with a loss of detectable
NA activity (Figs. 1b, 4b). (2) When the deﬁciency in viral
NA activity was compensated using bacterial NA, HN-
262?264?461 and HN-262?461—bound to receptors—
gain the ability to bind erythrocytes (Fig. 4a, c). The
observations of Connaris et al. [3] and Mirza et al. [20] can
be interpreted in the context of a similar NA-triggered
hemadsorption activity. Reduced erythrocyte binding of
mutated HN has been described to be accompanied by
strongly reduced NA activity.
Until now, the functional relevance of amino acids
262, 264 and 461 was neither recognizable from their
classiﬁcation as highly conserved amino acids nor by
identiﬁcation as active site residues due to structure anal-
ysis data. However, an inﬂuence on NA activity could be
suggested by the proximity of amino acids 262 and 264 to
the ‘‘NRKSCS motif’’ at positions 254–259 in SeV HN, a
highly conserved region among parainﬂuenzaviruses [20].
Moreover, conformational implications could also be
thought to have an inﬂuence, because positions 262 and
264 lie between C258 and C271, which form a disulﬁde
bridge in the human parainﬂuenzavirus 3 HN protein, the
closest ‘‘sequence’’ relative of the SeV HN [16].
Absence of NA activity was associated with a drastically
reduced HN content in mutant progeny particles generated
at 39C (Fig. 5). This is in accordance with earlier results
obtained with mutant ts 271. Reduced HN incorporation
into ts 271 virus particles occurred in combination with
signiﬁcantly reduced NA activity at elevated temperature
but without signiﬁcantly reduced virus budding [30, 35].
We assume that HN incorporation into virus particles
might be inhibited to the same extent that HN remains
bound to sialylated cell-surface components. The receptor-
cleavage function of newly synthesized HN seems to play
an essential role with regard to the HN content of virus
particles and consequently to the infectivity of viral
progeny.
Based on our results, the two steps of HN–receptor
interaction need to be interpreted in a new light: (1) HN
binds very efﬁciently to receptors, thus leading to quanti-
tative inhibition of receptor function, as demonstrated by
superinfection protection. (2) By cleavage of a neuraminic
acid residue by NA, the receptor is destroyed and, in par-
allel, HN is released from the complex, allowing it to be
incorporated into new virus particles. This situation is
thought to depend strictly on the amount of each of the two
binding partners present during the viral life cycle. When,
at the beginning of an infection, many receptors but only a
few HN molecules are present, all of the HN should be
bound to the receptors and have to be released by NA
action. However, later during infection, when HN is
expressed in excess, the majority of HN could follow the
secretory pathway without binding to receptors. Finally,
when HAd-competent HN molecules and destroyed
receptors are detectable at the surface of wt infected cells,
it is impossible to determine whether the HN and receptors
came in contact early in their pathways or whether this
interaction happened later on when receptors and HN were
already inserted into the cell membrane, or even when HN
was incorporated into the envelope of viral progeny.
Receptor inactivation in the absence of NA activity
during infections with mutant HN-262?461 and HN-
262?264?461 is a quantitative process. In order for this
process to reach adequate efﬁciency, we conclude that it
takes place soon after HN protein synthesis, before assem-
bly of progeny virus particles. Therefore, the mechanism
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123involved must differ from the receptor-destroying NA
activity during budding and re-binding of virus particles
[23]. When functional receptors would have to be cleaved
by newly assembled progeny virus as a requirement fortheir
release from the cell, it would be difﬁcult to explain for our
mutant virus by which mechanism superinfection of cells is
inhibited when NA is absent. The spread of paramyxovi-
ruses in tissues depends on the efﬁcient release of viral
progeny from primary infected cells, leading to further cell
infections. NA inhibitors are applied extracellularly to
inhibit that viral spread to neighboring cells [1, 38]. When,
as shown with our mutants, receptor inactivation and
receptor destruction are already ﬁnished before the process
of virus budding has started, the effects of antiviral drugs
should be rather directed toward preventing paramyxoviral
progeny from adsorption to new, uninfected cells. The
principle of early receptor inactivation by intracellular HN–
receptor binding—as supposed here—would allow virus
particles unimpeded release from infected cells, and this
would represent another example of viral evolution.
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